Candel Therapeutics (CADL) Q1 2026 earnings summary

Executive summary

• Focused on developing off-the-shelf viral immunotherapies for cancer, with lead candidates aglatimagene and linoserpaturev in advanced clinical trials for prostate cancer, NSCLC, and glioma.

• Positive phase 3 data for aglatimagene in localized prostate cancer; BLA submission planned for Q4 2026 and commercial launch preparations underway with EVERSANA and IDEA Pharma.

• Multiple regulatory designations (Fast Track, RMAT, Orphan Drug) granted for lead programs.

• Extended survival observed in aglatimagene trials for advanced NSCLC and localized prostate cancer; pivotal phase 3 NSCLC trial initiation planned for Q2 2026.

• Cash position of $194.8 million as of March 31, 2026, expected to fund operations into Q1 2028.

Financial highlights

• Cash and cash equivalents of $194.8 million as of March 31, 2026, up from $119.7 million at year-end 2025.

• Net loss of $8.9 million for Q1 2026, compared to net income of $7.4 million in Q1 2025, driven by higher R&D and G&A expenses.

• Operating expenses rose to $16.3 million in Q1 2026 from $8.1 million in Q1 2025, mainly due to increased clinical development and commercial readiness costs.

• $93.8 million raised in a follow-on equity offering in February 2026.

• Accumulated deficit of $239.2 million as of March 31, 2026.

Outlook and guidance

• Existing cash expected to fund operations into Q1 2028, supporting ongoing and planned clinical and commercial activities.

• Additional capital will be required for commercialization and further clinical development.

• Anticipates BLA submission for aglatimagene in prostate cancer in Q4 2026 and phase 3 trial initiation in NSCLC in Q2 2026.

• Extended follow-up and biomarker data from prostate cancer trials to be presented in May and Q3 2026, respectively.